The U.S. Patent and Trademark Office has issued U.S. Patent No. 6,238,662 entitled, "Synthetic Alpha-L-Iduronidase and Genetic Sequences Encoding Same." The patent claims are related to methods of treating Hurler syndrome, also know as mucopolysaccharidosis I (MPS I) using the purified alpha-L-iduronidase made from cells transfected with DNA encoding the protein. The patent, based on work performed by John Hopwood and colleagues who cloned the gene and cDNA for alpha-L-iduronidase and characterized the protein, was issued to Women's and Children's Hospital in North Adelaide, Australia and licensed to Transkaryotic Therapies (TKT), Inc. (9195 Albany St., Cambridge, MA 02139; Tel: 617/349-0200, Fax: 617/ 491-7903).
MPS I is a rare, inherited genetic lysosomal storage disorder caused by deficient activity of the protein alpha-L-iduronidase. Alpha-L-iduronidase I helps break down mucopolysaccharides. In patients affected by MPS I, mucopolysaccharides accumulate in organs and tissues of the body, particularly in the central nervous system, liver, spleen, heart, and skeleton ultimately lending to cell death and progressive tissue and organ damage. It is estimated that 1 in 25,000 births will result in some form of MPS in the United States.
"TKT intends to develop and commercialize a pipeline of products focused on rare genetic diseases including Fabry disease, Gaucher disease, Hunter syndrome, and Hurler syndrome," says Richard F Selden, president and CEO of TKT. "These are important patient populations that often get overlooked despite the fact that there is a great need for treatments, and we intend to be on the forefront of this research."
COPYRIGHT 2001 Business Communications Company, Inc.
COPYRIGHT 2001 Gale Group